CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
55.65
-0.76 (-1.35%)
Apr 24, 2024, 4:00 PM EDT - Market closed
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for CRSP stock have an average target of 81.44, with a low estimate of 30 and a high estimate of 160. The average target predicts an increase of 46.34% from the current stock price of 55.65.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRSP stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 7 | 7 | 7 | 9 | 9 | 7 |
| Sell | 1 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 19 | 19 | 21 | 21 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $88 → $89 | Strong Buy | Maintains | $88 → $89 | +59.93% | Apr 18, 2024 |
| Needham | Needham | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +61.73% | Apr 11, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $82 → $99 | Strong Buy | Maintains | $82 → $99 | +77.90% | Mar 6, 2024 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $46 → $48 | Sell | Maintains | $46 → $48 | -13.75% | Feb 26, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $57 → $66 | Hold | Maintains | $57 → $66 | +18.60% | Feb 22, 2024 |
Financial Forecast
Revenue This Year
111.31M
from 371.21M
Decreased by -70.01%
Revenue Next Year
417.60M
from 111.31M
Increased by 275.17%
EPS This Year
-5.80
from -1.94
EPS Next Year
-4.36
from -5.80
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 480.8M | 3.5B | 5.7B | 8.3B | 12.3B |
| Avg | 111.3M | 417.6M | 984.7M | 1.8B | 2.6B |
| Low | 14.7M | 39.2M | 88.2M | 188.2M | 245.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.5% | 3,023.7% | 1,268.5% | 742.4% | 592.0% |
| Avg | -70.0% | 275.2% | 135.8% | 80.2% | 48.3% |
| Low | -96.0% | -64.8% | -78.9% | -80.9% | -86.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.73 | 5.33 | 9.27 | 20.22 | 33.53 |
| Avg | -5.80 | -4.36 | -1.01 | 6.36 | 11.39 |
| Low | -7.34 | -7.79 | -7.10 | -3.59 | -3.17 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 427.1% |
| Avg | - | - | - | - | 79.1% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.